Search results
Results from the WOW.Com Content Network
The drug reached phase 3 clinical trials for treatment of fatigue prior to the discontinuation of its development for this use in January 2024. [32] Aside from the preceding indications, armodafinil is currently under development for the treatment of eating disorders and, as of January 2024, is in phase 3 trials for this use.
USP 800 (Hazardous Drugs—Handling in Healthcare Settings) is a guideline created by the United States Pharmacopeia Convention (USP), as one of their General Chapters through which the USP "sets quality standards for medicines, dietary supplements and food ingredients".
The original formula for Actifed contained pseudoephedrine hydrochloride 60 mg as the nasal decongestant and triprolidine hydrochloride 2.5 mg as the antihistamine. . However, in response to widespread laws requiring products containing pseudoephedrine to be kept behind the pharmacy counter, Pfizer changed Actifed's U.S. formula in late 2006 to contain phenylephrine HCl 10 mg as the nasal ...
The FDA issued a final rule on changes to the facts panel on May 27, 2016. [5] The new values were published in the Federal Register. [6] The original deadline to be in compliance was July 28, 2018, but on May 4, 2018, the FDA released a final rule that extended the deadline to January 1, 2020, for manufacturers with $10 million or more in annual food sales, and by January 1, 2021, for ...
Iron(III)-hydroxide polymaltose complex is a medication used to treat iron deficiency / iron deficiency anemia and belongs to the group of oral iron preparations.The preparation is a macromolecular complex, consisting of iron(III) hydroxide (trivalent iron, Fe 3+, Fe(OH) 3 ·H 2 O) and the carrier polymaltose and is available in solid form as a film-coated or chewable tablet and in liquid form ...
Diagnosed with leukemia three years ago, Tsoukalas, 26, was stunned to learn that her insurer’s coverage of the drug she needed came with a $13,000 monthly copay, which the recent college ...
Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema). It is available as a topical cream. It was developed and formerly marketed by Novartis under the trade name Elidel.
But the U.S. drug treatment system — which is mostly a hodgepodge of abstinence-only and 12-step-based facilities that resemble either minimum-security prisons or tropical spas — has for the most part ignored the medical science and been slow to embrace medication-assisted treatment, as The Huffington Post reported in January. As a result ...